Developing an Oncology Workforce for the 21st Century

培养 21 世纪的肿瘤学劳动力

• 批准号: 10683112
• 负责人: OLUFUNMILAYO F. OLOPADE
• 金额: $ 81.32万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-08-12 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10683112
• 关键词: Advisory Committees; Appointment; Award; Chicago; Clinical; Clinical Informatics; Clinical Oncology; Clinical Pharmacology; Clinical Research; Clinical Trials; Clinical Trials Network; Communities; Comprehensive Cancer Center; Country; Data Science; Doctor of Medicine; Doctor of Philosophy; Education; Elements; Entrepreneurship; Environment; Faculty; Funding; Genomics; Goals; Immunology; Immunotherapy; Institution; K-Series Research Career Programs; Master of Science; Medicine; Mentored Clinical Scientist Development Program; Mentors; Minority Groups; Nurses; Oncology; Paper; Peer Review; Pharmacogenomics; Phase; Postdoctoral Fellow; Principal Investigator; Productivity; Protocols documentation; Publishing; Qualifying; Research; Research Infrastructure; Research Personnel; Research Project Grants; Research Training; Scholars Program; Structure; Teacher Professional Development; Testing; Therapeutic Research; Training; Training Programs; Translational Research; United States National Institutes of Health; Universities; Woman; cancer clinical trial; cancer genomics; career; clinical investigation; design; flexibility; innovation; member; microbiome research; mid-career faculty; patient oriented research; phase III trial; programs; skills; training opportunity; underserved minority

PROJECT SUMMARY/ABSTRACT The overall goal of the dual-track University of Chicago Paul Calabresi Career Development Award for Clinical Oncology is to increase the number of highly skilled clinicians (M.D.s, D.O,s, Pharm.D., nurses with PhD or equivalent) and non-clinician postdoctoral researchers who are capable of designing and testing innovative hypothesis-driven clinical therapeutic research protocols in clinical trial settings (pilot/Phase I, Phase II and Phase III trials). To do this, we have created a tightly structured and mentored education program within an academically rigorous training environment that prepares the most compelling senior fellows or junior faculty in clinical oncology for careers in patient oriented research. The program is anchored within our Comprehensive Cancer Center and led by Olufunmilayo Olopade, MD along with Walter Stadler, MD with strong support from an Executive Committee as well as Internal and External Advisory Committees. The 78 research training faculty preceptors have NIH or equivalent peer- reviewed funding, interact on a number of collaborative research and training efforts and are well qualified to serve as potential mentors for the five trainees per year participating in this K12 program. Each trainee is appointed for a minimum of two years. In this renewal application, we shall continue successful elements of the program in clinical pharmacology, genomics and immunotherapy while enhancing training opportunities in emerging fields of clinical informatics, data science and microbiome research. The Paul Calabresi K12 Scholars Program is our highly mentored, didactic coursework-intensive program, and “hands on” clinical research training which results in a Master of Science in Clinical Investigation. Leveraging clinical research infrastructure across University of Chicago Medicine, we have also created a flexible set of integrated interdisciplinary courses in translational science that blends entrepreneurships, cancer genomics, immunology, pharmacogenomics and community based clinical trials network. Of the 18 trainees who have completed the program since 2010, 13 (72%) are currently in academic careers, of whom 7 (54%) hold appointments at the Associate Professor level. Moreover, these 18 trainees have published a total of 176 oncology research papers, and are Principal Investigators or Co-Investigators on 56 oncology research grant awards. Of significance, 7 of 14 (50%) appointments to the program in the last funding cycle were women or members of underserved minority groups. An explicit goal of this Paul Calabresi Scholars program, as with all training programs in our institution, is that its training opportunities and benefits will extend far beyond the relatively few scholars whose stipends it will provide. The program has had a transformative and global impact and is reaching into the larger oncology trainee community in Chicago and to trainees in other countries who come to our Institution as Global Oncology Scholars. Thus, the benefit that accrues from the program's implementation and productivity is substantial and will increase the number of highly skilled clinicians and non-clinicians conducting cancer clinical trials.

项目概要/摘要 芝加哥大学保罗·卡拉布雷西临床职业发展奖双轨制总体目标 肿瘤学旨在增加高技能临床医生（医学博士、医学博士、药学博士、拥有博士学位或博士学位的护士）的数量 同等水平）和能够设计和测试创新的非临床博士后研究人员 临床试验环境中假设驱动的临床治疗研究方案（试点/第一阶段、第二阶段和 III 期试验）。为此，我们创建了一个结构严密且受指导的教育计划 学术严谨的培训环境，培养最引人注目的高级研究员或初级教师 临床肿瘤学以患者为导向的研究职业。该计划以我们的综合计划为基础 癌症中心，由医学博士 Olufunmilayo Olopade 和医学博士 Walter Stadler 领导，并得到以下机构的大力支持 执行委员会以及内部和外部咨询委员会。 78 科研训练 教师导师拥有 NIH 或同等同行评审资金，在许多合作项目上进行互动 研究和培训工作，并且有资格担任每年五名学员的潜在导师 参加这个K12项目。每位实习生的任期至少为两年。在这次更新中 应用，我们将继续该计划在临床药理学、基因组学和 免疫疗法，同时增加临床信息学、数据科学新兴领域的培训机会 和微生物组研究。 Paul Calabresi K12 学者计划是我们高度指导、说教的项目 课程密集型课程和“实践”临床研究培训，从而获得理学硕士学位 临床研究。利用芝加哥大学医学院的临床研究基础设施，我们 还创建了一套灵活的转化科学综合跨学科课程，融合了 创业、癌症基因组学、免疫学、药物基因组学和社区临床试验 网络。自 2010 年以来完成该计划的 18 名学员中，有 13 名 (72%) 目前正在学术研究中 其中 7 人（54%）拥有副教授级别的职位。此外，这18名练习生 总共发表了 176 篇肿瘤学研究论文，并且是该领域的首席研究员或共同研究员 56 项肿瘤学研究补助金。值得注意的是，过去 14 次 (50%) 的项目预约中有 7 次 资助周期是妇女或服务不足的少数群体成员。这位保罗的明确目标 卡拉布雷西学者计划与我们机构的所有培训计划一样，其培训机会 其好处将远远超出其提供津贴的相对少数学者的范围。该计划 产生了变革性的全球影响，并正在进入更大的肿瘤学实习生社区 芝加哥以及其他国家的学员作为全球肿瘤学者来到我们机构。因此， 该计划的实施和生产力所带来的效益是巨大的，并将 增加进行癌症临床试验的高技能临床医生和非临床医生的数量。

项目成果

New Approaches to Treating Challenging Subtypes of ALL in AYA Patients.

• DOI: 10.1007/s11899-020-00597-y
• 发表时间: 2020-12
• 期刊: Current hematologic malignancy reports
• 影响因子: 2.9
• 作者: Prescott K;Jacobs M;Stock W;Wynne J
• 通讯作者: Wynne J

Bladder cancer pharmacogenomics: recent insights and future perspectives.

膀胱癌药物基因组学：最新见解和未来展望。

• DOI: 10.2217/pgs.12.145
• 发表时间: 2012
• 期刊: Pharmacogenomics
• 影响因子: 2.1
• 作者: O'Donnell,PeterH

Radiation-Induced Differentiated Thyroid Cancer Is Associated with Improved Overall Survival but Not Thyroid Cancer-Specific Mortality or Disease-Free Survival.

放射诱导的分化型甲状腺癌与总体生存率改善相关，但与甲状腺癌特异性死亡率或无病生存率无关。

• DOI: 10.1089/thy.2015.0634
• 发表时间: 2016
• 期刊: Thyroid : official journal of the American Thyroid Association
• 作者: White,MichaelG;Cipriani,NicoleA;Abdulrasool,Layth;Kaplan,Sharone;Aschebrook-Kilfoy,Briseis;Angelos,Peter;Kaplan,EdwinL;Grogan,RaymonH;Onel,Kenan
• 通讯作者: Onel,Kenan

Patient insights on features of an effective pharmacogenomics patient portal.

• DOI: 10.1097/fpc.0000000000000413
• 发表时间: 2020-12
• 期刊: Pharmacogenetics and genomics
• 影响因子: 2.6
• 作者: Truong TM;Lipschultz E;Schierer E;Danahey K;Ratain MJ;O'Donnell PH
• 通讯作者: O'Donnell PH

Mutational spectrum of breast cancer susceptibility genes among women ascertained in a cancer risk clinic in Northeast Brazil.

• DOI: 10.1007/s10549-022-06560-0
• 发表时间: 2022-06
• 期刊: BREAST CANCER RESEARCH AND TREATMENT
• 影响因子: 3.8
• 作者: Felix, Gabriela E. S.;Guindalini, Rodrigo Santa Cruz;Zheng, Yonglan;Walsh, Tom;Sveen, Elisabeth;Machado Lopes, Taisa Manuela;Cortes, Juliana;Zhang, Jing;Carozo, Polyanna;Santos, Irlania;Bonfim, Thais Ferreira;Garicochea, Bernardo;Pereira Toralles, Maria Betania;Meyer, Roberto;Netto, Eduardo Martins;Abe-Sandes, Kiyoko;King, Mary-Claire;de Oliveira Nascimento, Ivana Lucia;Olopade, Olufunmilayo, I
• 通讯作者: Olopade, Olufunmilayo, I